TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24493300

Group type: EXPERIMENTAL
Intervention: Clonidine hydrochloride (25 µg or 50 µg twice daily for 9 weeks)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo capsules for 9 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 120
Study: 22806348

Group type: EXPERIMENTAL
Intervention: Glucose-lowering drugs (non-insulin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neurotoxic ART
Number of subjects: 0

Group type: COMPARATOR
Intervention: Having APN
Number of subjects: 0
Study: 19241310

Group type: EXPERIMENTAL
Intervention: Fluvastatin (80 mg/day, n = 23)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (n = 23)
Number of subjects: 46
Study: 17335328

Group type: EXPERIMENTAL
Intervention: Nefazodone (300-600 mg/day, flexible dose)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 105
Study: 15467559

Group type: EXPERIMENTAL
Intervention: Intra-anal electromyographic biofeedback
Number of subjects: 60

Group type: COMPARATOR
Intervention: Electrical stimulation of the anal sphincter
Number of subjects: 60
Study: 12120116

Group type: EXPERIMENTAL
Intervention: Screening colonoscopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guidelines endorsement
Number of subjects: 0
Study: 9672928

Group type: EXPERIMENTAL
Intervention: Spinal/Epidural analgesia
Number of subjects: 26

Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 26

Group type: COMPARATOR
Intervention: Opioid analgesia with fentanyl
Number of subjects: 26
Study: 7561468

Group type: EXPERIMENTAL
Intervention: 0.5 per cent ephedrine hydrochloride nasal drops
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Betamethasone sodium phosphate (Betnosol) nose drops
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Alkaline nasal douches
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (no nasal medication)
Number of subjects: 97
Study: 2228922

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 461366

Group type: EXPERIMENTAL
Intervention: Azathioprin and Prednisone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D-Penicillamine and Prednisone
Number of subjects: 0
Study: 31870433

Group type: EXPERIMENTAL
Intervention: Pragmatic RCTs
Number of subjects: 45
Study: 27230119

Group type: EXPERIMENTAL
Intervention: School adjustment program for middle school transition
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1147
Study: 26559255

Group type: EXPERIMENTAL
Intervention: Folic Acid 0.4 mg/day (low-FA)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Folic Acid 0.8 mg/day (high-FA)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 450
Study: 25236946

Group type: EXPERIMENTAL
Intervention: Hypobaric bupivacaine 3.75 mg (B0.25 group)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Hypobaric bupivacaine 7.5 mg (B0.5 group)
Number of subjects: 64
Study: 22114872

Group type: EXPERIMENTAL
Intervention: Quercetin (500 mg capsules, once daily for 14 days)
Number of subjects: 16
Study: 20634634

Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum
Number of subjects: 76
Study: 17196713

Group type: EXPERIMENTAL
Intervention: Rapid schedule (Group R, vaccination on days 0, 7 and 21)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Accelerated conventional schedule (Group A, vaccination on days 0, 14 and 300)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Conventional schedule (Group C, vaccination on days 0, 28 and 300)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Modified conventional schedule (Group M, vaccination on days 0, 21 and 300)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Group R and Group C
Number of subjects: 398
Study: 15572425

Group type: EXPERIMENTAL
Intervention: KBC 30 mmol/d
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: KBC 60 mmol/d
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: KBC 90 mmol/d
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 12081581

Group type: EXPERIMENTAL
Intervention: Low-protein diet (0.6 g/kg/day)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Usual-protein diet (1.02 g/kg/day)
Number of subjects: 82
Study: 10360856

Group type: EXPERIMENTAL
Intervention: IL-2 alone
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Desflurane alone
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Desflurane plus IL-2
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no desflurane, no IL-2)
Number of subjects: 8
Study: 9638216

Group type: EXPERIMENTAL
Intervention: Apranax 550
Number of subjects: 60

Group type: COMPARATOR
Intervention: Voltaren 50
Number of subjects: 60
Study: 2778693

Group type: EXPERIMENTAL
Intervention: Ocufen (flurbiprofen) drops
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard dilating regimen (Control)
Number of subjects: 100
Study: 16794

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Noxiptyline
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dibenzepine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hamilton Rating Scale for depression
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hildreth Feeling Scale
Number of subjects: 30

Group type: COMPARATOR
Intervention: D Scale
Number of subjects: 30

Group type: COMPARATOR
Intervention: Trail Making Test
Number of subjects: 30
Study: 31507061

Group type: EXPERIMENTAL
Intervention: Population-based screening (PS)
Number of subjects: 1034

Group type: COMPARATOR
Intervention: Family-history (FH) testing
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: Both PS and FH groups
Number of subjects: 1034
Study: 31382835

Group type: EXPERIMENTAL
Intervention: Lutein water-soluble formulation
Number of subjects: 8

Group type: COMPARATOR
Intervention: Lutein oil suspension
Number of subjects: 8
Study: 28755807

Group type: EXPERIMENTAL
Intervention: Cholesterol lowering treatment (simvastatin 40 mg/day, ezetimibe/simvastatin 10/20 mg/day, ezetimibe/simvastatin 10/40 mg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combined treatment ezetimibe/simvastatin 10/40 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: CKD patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cholesterol lowering treatment
Number of subjects: 30
Study: 26887212

Group type: EXPERIMENTAL
Intervention: Acupuncture therapy combined with diet control and physical exercise
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group with diet control and physical exercise
Number of subjects: 60
Study: 22622437

Group type: EXPERIMENTAL
Intervention: High anxiety condition during target-directed aiming tasks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low anxiety condition during target-directed aiming tasks
Number of subjects: 0
Study: 21209230

Group type: EXPERIMENTAL
Intervention: Fosaprepitant 150 mg with oral dexamethasone (8 mg daily for 3 days)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Fosaprepitant 150 mg with oral midazolam (2 mg on days 1 and 4)
Number of subjects: 23
Study: 19737403

Group type: EXPERIMENTAL
Intervention: Collaborative Stepped Care (CSC)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 134
Study: 16288313

Group type: EXPERIMENTAL
Intervention: Genome wide linkage study
Number of subjects: 71
Study: 15324352

Group type: EXPERIMENTAL
Intervention: Sc/Rp + doxycycline polymer
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sc/Rp alone
Number of subjects: 15
Study: 11605086

Group type: EXPERIMENTAL
Intervention: Gaboxadol 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9255221

Group type: EXPERIMENTAL
Intervention: Insulin-like growth factor I (IGF-I)
Number of subjects: 0
Study: 7839427

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome) 1 mg/kg/day for 5 days
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome)
Number of subjects: 86
Study: 2512181

Group type: COMPARATOR
Intervention: hMG alone
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: hMG with leuprolide (GnRH-a)
Number of subjects: 27
Study: 31010491

Group type: EXPERIMENTAL
Intervention: Cognitive‐coupled Intensive Balance Training (CIBT) program
Number of subjects: 0
Study: 31952661

Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New systemic and surgical treatments
Number of subjects: 0
Study: 26330419

Group type: EXPERIMENTAL
Intervention: Absorb bioresorbable vascular scaffolds (BVSs)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Cobalt-chromium everolimus-eluting stents (CoCr-EESs)
Number of subjects: 400
Study: 24308189

Group type: EXPERIMENTAL
Intervention: EA plus sitting training
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sitting training (control)
Number of subjects: 120
Study: 21668564

Group type: EXPERIMENTAL
Intervention: Regular atrioventricular (AV) sequential pacing at 100 bpm for 30 minutes
Number of subjects: 22

Group type: COMPARATOR
Intervention: Irregular atrioventricular (AV) sequential pacing at 100 bpm for 30 minutes
Number of subjects: 22
Study: 19332193

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 2201

Group type: COMPARATOR
Intervention: Optimal medical treatment (MED)
Number of subjects: 2201

Group type: EXPERIMENTAL
Intervention: Stress testing (performed in 598 patients)
Number of subjects: 2201

Group type: EXPERIMENTAL
Intervention: Inducible ischemia (among patients with stress testing)
Number of subjects: 2201
Study: 16970535

Group type: EXPERIMENTAL
Intervention: Semistandardized acupuncture (12 sessions, at least six local and two distant points needled bilaterally from a selection of predefined points)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Minimal acupuncture (superficial needling of at least 6 of 10 predefined, bilateral, distant nonacupuncture points)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Waiting list control (2 months no acupuncture followed by semistandardized acupuncture)
Number of subjects: 301
Study: 12867204

Group type: EXPERIMENTAL
Intervention: 90 days of free treatment coupon
Number of subjects: 577

Group type: COMPARATOR
Intervention: Required to pay for treatment
Number of subjects: 577
Study: 11182626

Group type: EXPERIMENTAL
Intervention: Platelet GP IIb/IIIa receptor antagonists (abciximab, eptifibatide, tirofiban, lamifiban)
Number of subjects: 33000

Group type: EXPERIMENTAL
Intervention: Platelet GP IIb/IIIa receptor antagonists
Number of subjects: 33000

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 33000
Study: 9430504

Group type: EXPERIMENTAL
Intervention: Procaine (B)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (A)
Number of subjects: 34
Study: 8302193

Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Withdrawal of Zolpidem
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Withdrawal of Flunitrazepam
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Withdrawal of both drugs
Number of subjects: 30
Study: 3248317

Group type: EXPERIMENTAL
Intervention: Combination therapy with interferon and acyclovir or descyclovir (n = 25)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Interferon treatment alone (n = 10)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Acyclovir alone (n = 11)
Number of subjects: 146

Group type: COMPARATOR
Intervention: No treatment (n = 18)
Number of subjects: 146
Study: 31595825

Group type: EXPERIMENTAL
Intervention: Speed-goal group
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Quality-goal group
Number of subjects: 80
Study: 28398091

Group type: EXPERIMENTAL
Intervention: Downward social comparison photos and descriptive norms information
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Upward social comparison photos and descriptive norms information
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: No comparison photos and descriptive norms information
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: No photo and no comparison photos
Number of subjects: 223

Group type: COMPARATOR
Intervention: No descriptive norms information
Number of subjects: 223
Study: 28604014

Group type: EXPERIMENTAL
Intervention: Videoconferencing treatment for depression
Number of subjects: 0

Group type: COMPARATOR
Intervention: In-office treatment for depression
Number of subjects: 0
Study: 26632754

Group type: EXPERIMENTAL
Intervention: Very Low Carbohydrate (LC) diet (14% energy as carbohydrate [CHO < 50 g/day], 28% protein [PRO], 58% fat [<10% saturated fat])
Number of subjects: 115

Group type: COMPARATOR
Intervention: High Carbohydrate (HC) diet (53% CHO, 17% PRO, 30% fat [<10% saturated fat])
Number of subjects: 115
Study: 23183781

Group type: EXPERIMENTAL
Intervention: Smoke-free Kids program (n=728), 5 activity modules by mail at 4-week intervals
Number of subjects: 1398

Group type: COMPARATOR
Intervention: Control condition (n=750), fact-based intervention only
Number of subjects: 1398
Study: 21392685

Group type: EXPERIMENTAL
Intervention: Double extraction (deciduous canine and first molar)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Single extraction (1 deciduous canine)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 68
Study: 18924386

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 16570132

Group type: EXPERIMENTAL
Intervention: Tränkmann's jumping-the-bite appliance (JTB)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Comparison of treated groups (pre-pubertal vs pubertal)
Number of subjects: 2
Study: 14577360

Group type: EXPERIMENTAL
Intervention: Ampicillin orally 4 x 500 mg for 5 consecutive days
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Ampicillin orally 4 x 500 mg plus Gentamycin 2 x 80 mg i.m. for 3 to 5 days postoperatively
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: 3 x 2 g i.v. Cefazolin intraoperatively and 24 hours following the manipulation
Number of subjects: 172

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 172
Study: 11319569

Group type: EXPERIMENTAL
Intervention: Controlled-release diltiazem (diltiazem CR)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sustained-release nifedipine (nifedipine SR)
Number of subjects: 20
Study: 8855623

Group type: EXPERIMENTAL
Intervention: Interferon‐alpha plus retinoic acid concomitant with standard radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard radiotherapy
Number of subjects: 0
Study: 1290959

Group type: EXPERIMENTAL
Intervention: Fluconazole prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Empiric amphotericin B
Number of subjects: 0
Study: 6318170

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (0.625 mg)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Depo-medroxyprogesterone acetate (DMPA) (150 mg intramuscular injection)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conjugated estrogens
Number of subjects: 43

Group type: COMPARATOR
Intervention: Depo-medroxyprogesterone acetate (DMPA)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conjugated estrogens and DMPA
Number of subjects: 43
Study: 31175352

Group type: EXPERIMENTAL
Intervention: Escitalopram followed by venlafaxine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Remitted patients (control group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Depressed patients
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Remitting vs nonremitting acute patients
Number of subjects: 20
Study: 29534210

Group type: EXPERIMENTAL
Intervention: Focus on the Future intervention (single-session, clinic-based)
Number of subjects: 394
Study: 27198039

Group type: EXPERIMENTAL
Intervention: Curanderismo treatment (33 sessions over 10 months)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 1
Study: 24627538

Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 47

Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 47
Study: 21088046

Group type: EXPERIMENTAL
Intervention: Total sleep deprivation (2 nights)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Rapid eye movement sleep deprivation (4 nights)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (regular nights of sleep)
Number of subjects: 32
Study: 21097420

Group type: EXPERIMENTAL
Intervention: Continuous rocuronium infusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: No supplemental muscle relaxants (Group A)
Number of subjects: 40
Study: 17916229

Group type: EXPERIMENTAL
Intervention: Rofecoxib (25 mg q.d.)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg b.i.d.)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg b.i.d.)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 16123370

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 12201356

Group type: EXPERIMENTAL
Intervention: Vitamin C supplement (two tablets daily)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 10444118

Group type: EXPERIMENTAL
Intervention: 20 microg intranasal desmopressin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 40 microg intranasal desmopressin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7774832

Group type: COMPARATOR
Intervention: CAP (cyclophosphamide‐doxorubicin‐cisplatin)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: SRCA-guided chemotherapy
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: CACAR (cyclophosphamide‐doxorubicin‐carboplatin)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: SRCA-CAP
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: CAP (guided by SRCA)
Number of subjects: 196

Group type: COMPARATOR
Intervention: CAP (not guided by SRCA)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: SRCA arm
Number of subjects: 196

Group type: COMPARATOR
Intervention: CAP arm
Number of subjects: 196
Study: 2317911

Group type: COMPARATOR
Intervention: Exercise without calorie restriction (n = 46)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Calorie restriction without exercise (n = 42)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Control (n = 42)
Number of subjects: 130
Study: 7028257

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (600 mg/m²), doxorubicin (40 mg/m²), and cisplatin (50 mg/m²) every 3 weeks (Group 1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (600 mg/m²), doxorubicin (40 mg/m²), and cisplatin (100 mg/m²) every 3 weeks (Group 2)
Number of subjects: 50
Study: 31899570

Group type: EXPERIMENTAL
Intervention: Cetirizine (2 mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (2.2 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 12
Study: 31410902

Group type: COMPARATOR
Intervention: High confidence in negative shedding status
Number of subjects: 11061

Group type: COMPARATOR
Intervention: Potential for misclassification of shedding status
Number of subjects: 11061

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 11061
Study: 28683806

Group type: EXPERIMENTAL
Intervention: HMS BAB training intervention (one-day competency-based training followed by 8 weeks of peer-based practice)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no training intervention)
Number of subjects: 38
Study: 25938834

Group type: EXPERIMENTAL
Intervention: Magnesium isoglycyrrhizinate (experimental group; n=114)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Glutathione (control group; n=102)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Magnesium isoglycyrrhizinate (experimental group)
Number of subjects: 216
Study: 24075073

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 21849241

Group type: EXPERIMENTAL
Intervention: Electroacupuncture stimulation (EAS) at GB37
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Electroacupuncture stimulation (EAS) at KI8
Number of subjects: 28
Study: 19680668

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with 1/200,000 epinephrine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 60
Study: 17509880

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Evening primrose oil (EPO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study: 15226210

Group type: EXPERIMENTAL
Intervention: Brachytherapy (Guidant Galileo System)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (Coronary stenting)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Reference vessel
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin
Number of subjects: 27
Study: 11810791

Group type: EXPERIMENTAL
Intervention: Newer antihypertensive drugs (ACE inhibitors, calcium antagonists, alpha-blockers)
Number of subjects: 58000

Group type: COMPARATOR
Intervention: Older antihypertensive drugs (thiazide diuretics, beta-blockers)
Number of subjects: 58000
Study: 9773792

Group type: EXPERIMENTAL
Intervention: ADPKD children
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: ADPKD children with severe renal cystic disease (> 10 cysts)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: ADPKD children diagnosed after the first year of life
Number of subjects: 189
Study: 7940328

Group type: EXPERIMENTAL
Intervention: Single intraarticular injection of triamcinolone acetonide +/‐ cyclophosphamide
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Single intraarticular injection of glucocorticosteroids (methylprednisolone acetate, triamcinolone acetonide, composition with cyclophosphamide and dimethylsulfoxide)
Number of subjects: 112